Furthermore, this system can be used to evaluate the sensitivity of cancers in individual patients to immunotherapies targeting cytotoxic CD8+ T cells, such as monoclonal antibodies against PD-1 (also known as PDCD1) and PD-L1 (or CD274). Here, PDCD1 is linked to cancer.